Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 7 (2010), Issue 5 (May)

1. Bilateral EKOS EndoWave catheter thrombolysis of acute bilateral pulmonary embolism in a hemodynamically unstable patient.
   South Med J, 103(5): 455-7. [Abstract] [Full-text]
2. No change in the incidence of ampicillin-resistant, neonatal, early-onset sepsis over 18 years.
   Pediatrics, 125(5): e1031-8. [Abstract] [Full-text]
3. Prime-time hypoglycemia: factitious hypoglycemia during insulin-pump therapy.
   Pediatrics, 125(5): e1246-8. [Abstract] [Full-text]
4. Postmenopausal hormone therapy increases retinal blood flow and protects the retinal nerve fiber layer.
   Invest Ophthalmol Vis Sci, 51(5): 2587-600. [Abstract] [Full-text]
5. A high-throughput biophotonics instrument to screen for novel ocular photosensitizing therapeutic agents.
   Invest Ophthalmol Vis Sci, 51(5): 2705-20. [Abstract] [Full-text]
6. Secondary structure of cell-penetrating peptides controls membrane interaction and insertion.
   Biochim Biophys Acta, 1798(6): 1119-28. [Abstract] [Full-text]
7. Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo.
   Cancer Lett, 293(1): 99-108. [Abstract] [Full-text]
8. Do the dose or route of administration of norethisterone acetate as a part of hormone therapy play a role in risk of breast cancer: national-wide case-control study from Finland.
   Int J Cancer, 127(1): 185-9. [Abstract] [Full-text]
9. Tuning the insertion properties of pHLIP.
   Biochim Biophys Acta, 1798(6): 1041-6. [Abstract] [Full-text]
10. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence.
    Cancer, 116(10): 2360-5. [Abstract] [Full-text]
11. A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid.
    Cancer, 116(10): 2465-75. [Abstract] [Full-text]
12. Medication errors involving oral chemotherapy.
    Cancer, 116(10): 2455-64. [Abstract] [Full-text]
13. Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer.
    Cancer, 116(10): 2401-8. [Abstract] [Full-text]
14. A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer.
    Cancer, 116(10): 2301-6. [Abstract] [Full-text]
15. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer.
    Cancer, 116(10): 2322-31. [Abstract] [Full-text]
16. Phase 2 trial of pemetrexed disodium and carboplatin in previously untreated extensive-stage small cell lung cancer, N0423.
    Cancer, 116(10): 2382-9. [Abstract] [Full-text]
17. Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium.
    Cancer, 116(10): 2448-54. [Abstract] [Full-text]
18. Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: updated subgroup meta-analyses of overall survival.
    Jpn J Clin Oncol, 40(5): 432-41. [Abstract] [Full-text]
19. Health-related quality of life in patients with colorectal cancer who receive oral uracil and tegafur plus leucovorin.
    Jpn J Clin Oncol, 40(5): 412-9. [Abstract] [Full-text]
20. Induction chemotherapy with nedaplatin with 5-FU followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
    Jpn J Clin Oncol, 40(5): 425-31. [Abstract] [Full-text]
21. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis.
    JAMA, 303(17): 1729-37. [Abstract] [Full-text]
22. Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields.
    Proc Natl Acad Sci U S A, 107(18): 8346-51. [Abstract] [Full-text]
23. Raman spectroscopy study of phosphorus-containing dendrimers built from thiophosphoryl core.
    Spectrochim Acta A Mol Biomol Spectrosc, 76(2): 276-82. [Abstract] [Full-text]
24. Comparison of the efficacy of Rose Bengal and erythrosin in photodynamic therapy against Enterobacteriaceae.
    Lasers Med Sci, 25(4): 581-6. [Abstract] [Full-text]
25. Laser-induced effects in different biological samples.
    Lasers Med Sci, 25(4): 545-50. [Abstract] [Full-text]
26. Photodynamic therapy as an adjunctive treatment for chronic periodontitis: a meta-analysis.
    Lasers Med Sci, 25(4): 605-13. [Abstract] [Full-text]
27. Effect of bar-code technology on the safety of medication administration.
    N Engl J Med, 362(18): 1698-707. [Abstract] [Full-text]
28. Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone mineral density.
    J Pediatr Hematol Oncol, 32(4): 267-73. [Abstract] [Full-text]
29. Retropharyngeal neuroblastoma in an infant: management without surgery.
    J Pediatr Hematol Oncol, 32(4): e160-3. [Abstract] [Full-text]
30. Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008.
    J Clin Endocrinol Metab, 95(5): 2227-33. [Abstract] [Full-text]
31. "Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
    J Med Chem, 53(9): 3480-8. [Abstract] [Full-text]
32. Targeting multiple chorismate-utilizing enzymes with a single inhibitor: validation of a three-stage design.
    J Med Chem, 53(9): 3718-29. [Abstract] [Full-text]
33. Multiple unrelated chromosomal abnormalities in host cells after cord blood transplantation.
    J Pediatr Hematol Oncol, 32(4): 332-5. [Abstract] [Full-text]
34. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.
    J Clin Oncol, 28(14): 2339-47. [Abstract] [Full-text]
35. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.
    J Clin Oncol, 28(14): 2373-80. [Abstract] [Full-text]
36. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.
    J Clin Oncol, 28(14): 2430-6. [Abstract] [Full-text]
37. Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117.
    J Clin Oncol, 28(14): 2475-80. [Abstract] [Full-text]
38. AC133 expression in egyptian children with acute leukemia: impact on treatment response and disease outcome.
    J Pediatr Hematol Oncol, 32(4): 286-93. [Abstract] [Full-text]
39. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability.
    Blood, 115(18): 3671-7. [Abstract] [Full-text]
40. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation.
    Blood, 115(18): 3664-70. [Abstract] [Full-text]
41. Is sclerotherapy better than intralesional excision for treating aneurysmal bone cysts?
    Clin Orthop Relat Res, 468(6): 1649-59. [Abstract] [Full-text]
42. Clinical experience using 5% hypertonic saline as a safe alternative fluid for use in trauma.
    J Trauma, 68(5): 1172-7. [Abstract] [Full-text]
43. Problems of nonadherence in cardiology and proposals to improve outcomes.
    Am J Cardiol, 105(10): 1495-501. [Abstract] [Full-text]
44. Acute arterial hemorrhage following radiotherapy of oropharyngeal squamous cell carcinoma.
    Strahlenther Onkol, 186(5): 269-73. [Abstract] [Full-text]
45. Postoperative fluid management in major elective plastic surgery.
    J Plast Reconstr Aesthet Surg, 63(6): 992-5. [Abstract] [Full-text]
46. Photodynamic therapy targeting neuropilin-1: Interest of pseudopeptides with improved stability properties.
    Biochem Pharmacol, 80(2): 226-35. [Abstract] [Full-text]
47. Multivalent dendrimeric and monomeric adenosine agonists attenuate cell death in HL-1 mouse cardiomyocytes expressing the A(3) receptor.
    Biochem Pharmacol, 80(2): 188-96. [Abstract] [Full-text]
48. MYCN oncoprotein targets and their therapeutic potential.
    Cancer Lett, 293(2): 144-57. [Abstract] [Full-text]
49. Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo.
    Cancer Lett, 293(2): 158-66. [Abstract] [Full-text]
50. Delivery of paclitaxel from cobalt-chromium alloy surfaces without polymeric carriers.
    Biomaterials, 31(20): 5372-84. [Abstract] [Full-text]
51. Hyperbranched poly(amine-ester) based hydrogels for controlled multi-drug release in combination chemotherapy.
    Biomaterials, 31(20): 5445-54. [Abstract] [Full-text]
52. The effects of the electro-photodynamic in vitro treatment on human lung adenocarcinoma cells.
    Bioelectrochemistry, 79(1): 90-4. [Abstract] [Full-text]
53. Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer.
    Int J Radiat Oncol Biol Phys, 77(2): 447-54. [Abstract] [Full-text]
54. A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck.
    Int J Radiat Oncol Biol Phys, 77(2): 430-7. [Abstract] [Full-text]
55. Gastric perforation following cytoreductive surgery with perioperative intraperitoneal chemotherapy.
    J Surg Oncol, 101(7): 634-6. [Abstract] [Full-text]
56. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.
    J Surg Oncol, 101(7): 587-92. [Abstract] [Full-text]
57. Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer.
    Br J Cancer, 102(10): 1468-73. [Abstract] [Full-text]
58. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
    Cochrane Database Syst Rev, 5: CD006301. [Abstract] [Full-text]
59. WITHDRAWN: Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction.
    Cochrane Database Syst Rev, 5: CD004063. [Abstract] [Full-text]
60. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis.
    Cochrane Database Syst Rev, 5: CD002941. [Abstract] [Full-text]
61. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies.
    Gynecol Oncol, 117(3): 473-6. [Abstract] [Full-text]
62. Weekly methotrexate (50mg/m(2)) without dose escalation as a primary regimen for low-risk gestational trophoblastic neoplasia.
    Gynecol Oncol, 117(3): 477-80. [Abstract] [Full-text]
63. Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience.
    Gynecol Oncol, 117(3): 467-72. [Abstract] [Full-text]
64. Individual drug sampling does not supplant the need for head-to-head trials in dermatology.
    J Am Acad Dermatol, 62(6): 1062-3. [Abstract] [Full-text]
65. Autologous blood pleurodesis in rats to elucidate the amounts of blood required for reliable and reproducible results.
    J Surg Res, 161(2): 228-32. [Abstract] [Full-text]
66. Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.
    Cancer Genet Cytogenet, 199(2): 110-20. [Abstract] [Full-text]
67. Multidisciplinary intervention to identify and resolve drug-related problems in Norwegian nursing homes.
    Scand J Prim Health Care, 28(2): 82-8. [Abstract] [Full-text]
68. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy.
    J Infect Dis, 201(12): 1796-805. [Abstract] [Full-text]
69. Microbubble mediated sonoporation of cells in suspension: clonogenic viability and influence of molecular size on uptake.
    Ultrasonics, 50(7): 691-7. [Abstract] [Full-text]
70. Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors.
    Cancer Chemother Pharmacol, 66(2): 389-94. [Abstract] [Full-text]
71. Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer.
    Cancer Chemother Pharmacol, 66(2): 395-403. [Abstract] [Full-text]
72. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Cancer Chemother Pharmacol, 66(2): 373-80. [Abstract] [Full-text]
73. Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?
    Cancer Chemother Pharmacol, 66(2): 333-43. [Abstract] [Full-text]
74. Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy.
    Cancer Chemother Pharmacol, 66(2): 269-76. [Abstract] [Full-text]
75. Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer.
    Cancer Chemother Pharmacol, 66(2): 295-301. [Abstract] [Full-text]
76. A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer.
    Cancer Chemother Pharmacol, 66(2): 287-94. [Abstract] [Full-text]
77. Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents.
    Cancer Chemother Pharmacol, 66(2): 245-54. [Abstract] [Full-text]
78. Translational medicine 2.0: from clinical diagnosis-based to molecular-targeted therapies in the era of globalization.
    Clin Pharmacol Ther, 87(6): 642-5. [Abstract] [Full-text]
79. Legal developments and practical implications of gene patenting on targeted drug discovery and development.
    Clin Pharmacol Ther, 87(6): 633-5. [Abstract] [Full-text]
80. Out-of-pocket burden of health care spending and the adequacy of the Medicare Part D low-income subsidy.
    Med Care, 48(6): 503-9. [Abstract] [Full-text]
81. Central and peripheral molecular targets for antiobesity pharmacotherapy.
    Clin Pharmacol Ther, 87(6): 652-62. [Abstract] [Full-text]
82. Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes.
    J Virol, 84(12): 5986-96. [Abstract] [Full-text]
83. An in vitro intact globe expansion method for evaluation of cross-linking treatments.
    Invest Ophthalmol Vis Sci, 51(6): 3120-8. [Abstract] [Full-text]
84. In vitro photodynamic therapy and quantitative structure-activity relationship studies with stable synthetic near-infrared-absorbing bacteriochlorin photosensitizers.
    J Med Chem, 53(10): 4018-27. [Abstract] [Full-text]
85. Synthesis of DOTA-conjugated multimeric [Tyr3]octreotide peptides via a combination of Cu(I)-catalyzed "click" cycloaddition and thio acid/sulfonyl azide "sulfo-click" amidation and their in vivo evaluation.
    J Med Chem, 53(10): 3944-53. [Abstract] [Full-text]
86. Honokiol induces paraptosis and apoptosis and exhibits schedule-dependent synergy in combination with imatinib in human leukemia cells.
    Toxicol Mech Methods, 20(5): 234-41. [Abstract] [Full-text]
87. High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma.
    Pediatr Blood Cancer, 55(1): 149-52. [Abstract] [Full-text]
88. Results of a prospective study for the treatment of unilateral retinoblastoma.
    Pediatr Blood Cancer, 55(1): 60-6. [Abstract] [Full-text]
89. Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma.
    Pediatr Blood Cancer, 55(1): 55-9. [Abstract] [Full-text]
90. Sperm analysis of patients after successful treatment of childhood acute lymphoblastic leukemia with chemotherapy.
    Pediatr Blood Cancer, 55(1): 208-10. [Abstract] [Full-text]
91. Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation.
    Pediatr Blood Cancer, 55(1): 42-6. [Abstract] [Full-text]
92. New generation of chitosan-encapsulated ZnO quantum dots loaded with drug: synthesis, characterization and in vitro drug delivery response.
    Acta Biomater, 6(7): 2732-9. [Abstract] [Full-text]
93. Retrospective comparison of mechanical percutaneous thrombectomy of hemodialysis arteriovenous grafts with the Arrow-Trerotola device and the lyse and wait technique.
    AJR Am J Roentgenol, 194(6): 1626-9. [Abstract] [Full-text]
94. Self-assembly of Janus dendrimers into uniform dendrimersomes and other complex architectures.
    Science, 328(5981): 1009-14. [Abstract] [Full-text]
95. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.
    Science, 328(5981): 1031-5. [Abstract] [Full-text]
96. Normal targeting of a tagged Kv1.5 channel acutely transfected into fresh adult cardiac myocytes by a biolistic method.
    Am J Physiol Cell Physiol, 298(6): C1343-52. [Abstract] [Full-text]
97. A comprehensive review of Paget-Schroetter syndrome.
    J Vasc Surg, 51(6): 1538-47. [Abstract] [Full-text]
98. Chemotherapy-induced mesenchymal stem cell damage in patients with hematological malignancy.
    Ann Hematol, 89(7): 701-13. [Abstract] [Full-text]
99. Synergistic protection in lung ischemia-reperfusion injury with calcineurin and thrombin inhibition.
    Ann Thorac Surg, 89(6): 1766-71. [Abstract] [Full-text]
100. Photodynamic laser therapy for lesions in the airway.
     Ann Thorac Surg, 89(6): 1744-8; discussion 1748-9. [Abstract] [Full-text]
101. A prospective observational study of medication errors in a tertiary care emergency department.
     Ann Emerg Med, 55(6): 522-6. [Abstract] [Full-text]
102. Medication errors recovered by emergency department pharmacists.
     Ann Emerg Med, 55(6): 513-21. [Abstract] [Full-text]
103. Defining risk status in the first-line treatment of metastatic renal cell carcinoma.
     J Cancer Res Clin Oncol, 136(7): 961-8. [Abstract] [Full-text]
104. The coffee diterpene kahweol sensitizes TRAIL-induced apoptosis in renal carcinoma Caki cells through down-regulation of Bcl-2 and c-FLIP.
     Chem Biol Interact, 186(1): 36-42. [Abstract] [Full-text]
105. Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.
     Leuk Res, 34(7): 954-7. [Abstract] [Full-text]
106. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
     Leuk Res, 34(7): 864-70. [Abstract] [Full-text]
107. Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients.
     Leuk Res, 34(7): 942-5. [Abstract] [Full-text]
108. Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer.
     J Cancer Res Clin Oncol, 136(7): 1029-37. [Abstract] [Full-text]
109. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
     Leuk Res, 34(7): 877-82. [Abstract] [Full-text]
110. Evaluation of azithromycin, trovafloxacin and grepafloxacin as prophylaxis for experimental murine melioidosis.
     Int J Antimicrob Agents, 36(1): 87-9. [Abstract] [Full-text]
111. Evaluation of azithromycin, trovafloxacin and grepafloxacin as prophylaxis against experimental murine Brucella melitensis infection.
     Int J Antimicrob Agents, 36(1): 66-8. [Abstract] [Full-text]
112. Novel casein hydrogels: formation, structure and controlled drug release.
     Colloids Surf B Biointerfaces, 79(1): 142-8. [Abstract] [Full-text]
113. Stroke team remote evaluation using a digital observation camera in Arizona: the initial mayo clinic experience trial.
     Stroke, 41(6): 1251-8. [Abstract] [Full-text]
114. CYP3A4-Mediated oxygenation versus dehydrogenation of raloxifene.
     Biochemistry, 49(21): 4466-75. [Abstract] [Full-text]
115. Dissemination of thrombolysis for acute ischemic stroke across a nation: experiences from the Swedish stroke register, 2003 to 2008.
     Stroke, 41(6): 1115-22. [Abstract] [Full-text]
116. Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer.
     Cancer, 116(11): 2511-8. [Abstract] [Full-text]
117. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.
     Cancer, 116(11): 2655-64. [Abstract] [Full-text]
118. Fertility preservation in women with breast cancer undergoing adjuvant chemotherapy: a systematic review.
     Fertil Steril, 94(1): 138-43. [Abstract] [Full-text]
119. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches.
     Acta Trop, 115(1): 55-68. [Abstract] [Full-text]
120. Should in-line filters be used in peripheral intravenous catheters to prevent infusion-related phlebitis? A systematic review of randomized controlled trials.
     Anesth Analg, 110(6): 1624-9. [Abstract] [Full-text]
121. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen.
     Prostate, 70(10): 1127-33. [Abstract] [Full-text]
122. Adherence to perinatal group B streptococcal prevention guidelines.
     Obstet Gynecol, 115(6): 1217-24. [Abstract] [Full-text]
123. Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barrett's oesophagus following photodynamic therapy.
     Br J Cancer, 102(11): 1608-17. [Abstract] [Full-text]
124. Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer.
     J Cancer Res Clin Oncol, 136(7): 1059-64. [Abstract] [Full-text]
125. Enhancement of chemotherapeutic agent-induced apoptosis by inhibition of NF-kappaB using ursolic acid.
     Int J Cancer, 127(2): 462-73. [Abstract] [Full-text]
126. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer.
     Int J Cancer, 127(2): 257-68. [Abstract] [Full-text]
127. Impact of hepatitis C virus coinfection on HAART in HIV-infected individuals: multicentric observation cohort.
     J Acquir Immune Defic Syndr, 54(2): 137-42. [Abstract] [Full-text]
128. Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review.
     J Acquir Immune Defic Syndr, 54(2): 167-79. [Abstract] [Full-text]
129. Long-term effect of sciatic nerve block with slow-release lidocaine in a rat model of postoperative pain.
     Anesthesiology, 112(6): 1473-81. [Abstract] [Full-text]
130. Randomized phase 2 dose-finding study of weekly administration of darbepoetin alpha in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapy.
     Jpn J Clin Oncol, 40(6): 521-9. [Abstract] [Full-text]
131. Combination therapy of interleukin-2 and sorafenib improves survival benefits and prevents spontaneous pulmonary metastasis in murine renal cell carcinoma models.
     Jpn J Clin Oncol, 40(6): 503-7. [Abstract] [Full-text]
132. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.
     Blood, 115(21): 4168-73. [Abstract] [Full-text]
133. Encapsulated plant extract (Gelsemium sempervirens) poly (lactide-co-glycolide) nanoparticles enhance cellular uptake and increase bioactivity in vitro.
     Exp Biol Med (Maywood), 235(6): 678-88. [Abstract] [Full-text]
134. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data.
     J Am Coll Cardiol, 55(22): 2435-45. [Abstract] [Full-text]
135. Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials.
     Am J Ophthalmol, 149(6): 939-946.e1. [Abstract] [Full-text]
136. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy.
     Am J Ophthalmol, 149(6): 947-954.e1. [Abstract] [Full-text]
137. Hormone therapy, DNA methylation and colon cancer.
     Carcinogenesis, 31(6): 1060-7. [Abstract] [Full-text]
138. Concurrent chemoradiotherapy with helical tomotherapy for oropharyngeal cancer: a preliminary result.
     Int J Radiat Oncol Biol Phys, 77(3): 715-21. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.